Gross Margin % is calculated as gross profit divided by its revenue. Gamida Cell's Gross Profit for the
three
months ended in Dec. 2023 was $-3.80 Mil. Gamida Cell's Revenue for the
three
months ended in Dec. 2023 was $1.11 Mil. Therefore, Gamida Cell's Gross Margin % for the quarter that ended in Dec. 2023 was -341.85%.
The historical rank and industry rank for Gamida Cell's Gross Margin % or its related term are showing as below:
GMDAQ'
s Gross Margin % Range Over the Past 10 Years
Min: -210.26 Med: -210.26 Max: -210.26
Current: -210.26
During the past 8 years, the highestGross Margin % of Gamida Cell was -210.26%. The lowest was -210.26%. And the median was -210.26%.
GMDAQ's Gross Margin % is ranked worse than 97.14% of 735
companies
in the Biotechnology industry
Industry Median: 59.4
vs GMDAQ: -210.26
Gamida Cell had a gross margin of -341.85% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Gamida Cell was 0.00% per year.
Gamida Cell Gross Margin % Historical Data
The historical data trend for Gamida Cell's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gamida Cell's Gross Margin %
For the Biotechnology subindustry, Gamida Cell's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gamida Cell's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gamida Cell's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Gamida Cell's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Gamida Cell had a gross margin of -341.85% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Gamida Cell Gross Margin % Related Terms
Thank you for viewing the detailed overview of Gamida Cell's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GMDAQ has been successfully added to your 